| Dr Min-shue Alvin Chen, MD | |
|
1221 Mercantile Ln, Upper Marlboro, MD 20774-5374 | |
| (301) 386-6718 | |
| Not Available |
| Full Name | Dr Min-shue Alvin Chen |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Location | 1221 Mercantile Ln, Upper Marlboro, Maryland |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1396060497 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | MD042918 (District Of Columbia) | Secondary |
| 207L00000X | Anesthesiology | D78980 (Maryland) | Primary |
| Entity Name | Kaiser Foundation Health Plan Of The Mid-atlantic States,inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952461816 PECOS PAC ID: 3779495858 Enrollment ID: O20040105000308 |
News Archive
Neuralstem, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to initiate a Phase Ia safety trial to test NSI-189, its first small molecule compound, in major depression. NSI-189 is a proprietary new chemical entity discovered by Neuralstem that stimulates new neuron growth in the hippocampus, an area of the brain that is believed to be involved in depression and other diseases, such as Alzheimer's disease.
Eli Lilly and Company announced today that its global Phase III trial evaluating ALIMTA (pemetrexed for injection) in combination with cisplatin in patients with recurrent or metastatic squamous cell cancer of the head and neck (SCCHN) did not meet its primary endpoint for overall survival. Data were presented for the first time today at the 35th Annual Meeting of the European Society for Medical Oncology (ESMO).
Millions of lives are threatened by the dual epidemics of diabetes and obesity that are bound to explode in this century, international diabetes and obesity organizations said today in the run up to World Diabetes Day.
Compliance with proposed emergency department length of stay measures for admitted, discharged, transferred, and observed patients does not differ significantly between safety-net hospitals (which serve higher proportion of patients with poorer health care status) and non-safety-net hospitals, addressing the issue of whether safety-net hospitals may not be able to meet certain performance measures and could be at risk of reduced funding, according to a study in the February 1 issue of JAMA.
Researchers in the UK have warned that a widespread mutation that has arisen in the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) appears to escape recognition by CD8 T-cell responses in both convalescent patients and recipients of the current coronavirus disease 2019 (COVID-19) vaccines.
› Verified 8 days ago
| Entity Name | Kaiser Foundation Health Plan Of The Mid-atlantic States,inc |
|---|---|
| Entity Type | Part B Supplier - Ambulatory Surgical Center |
| Entity Identifiers | NPI Number: 1578638425 PECOS PAC ID: 3779495858 Enrollment ID: O20040805001280 |
News Archive
Neuralstem, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to initiate a Phase Ia safety trial to test NSI-189, its first small molecule compound, in major depression. NSI-189 is a proprietary new chemical entity discovered by Neuralstem that stimulates new neuron growth in the hippocampus, an area of the brain that is believed to be involved in depression and other diseases, such as Alzheimer's disease.
Eli Lilly and Company announced today that its global Phase III trial evaluating ALIMTA (pemetrexed for injection) in combination with cisplatin in patients with recurrent or metastatic squamous cell cancer of the head and neck (SCCHN) did not meet its primary endpoint for overall survival. Data were presented for the first time today at the 35th Annual Meeting of the European Society for Medical Oncology (ESMO).
Millions of lives are threatened by the dual epidemics of diabetes and obesity that are bound to explode in this century, international diabetes and obesity organizations said today in the run up to World Diabetes Day.
Compliance with proposed emergency department length of stay measures for admitted, discharged, transferred, and observed patients does not differ significantly between safety-net hospitals (which serve higher proportion of patients with poorer health care status) and non-safety-net hospitals, addressing the issue of whether safety-net hospitals may not be able to meet certain performance measures and could be at risk of reduced funding, according to a study in the February 1 issue of JAMA.
Researchers in the UK have warned that a widespread mutation that has arisen in the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) appears to escape recognition by CD8 T-cell responses in both convalescent patients and recipients of the current coronavirus disease 2019 (COVID-19) vaccines.
› Verified 8 days ago
| Entity Name | Kaiser Foundation Health Plan Of The Mid-atlantic States,inc |
|---|---|
| Entity Type | Part B Supplier - Ambulatory Surgical Center |
| Entity Identifiers | NPI Number: 1073678637 PECOS PAC ID: 3779495858 Enrollment ID: O20100729000796 |
News Archive
Neuralstem, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to initiate a Phase Ia safety trial to test NSI-189, its first small molecule compound, in major depression. NSI-189 is a proprietary new chemical entity discovered by Neuralstem that stimulates new neuron growth in the hippocampus, an area of the brain that is believed to be involved in depression and other diseases, such as Alzheimer's disease.
Eli Lilly and Company announced today that its global Phase III trial evaluating ALIMTA (pemetrexed for injection) in combination with cisplatin in patients with recurrent or metastatic squamous cell cancer of the head and neck (SCCHN) did not meet its primary endpoint for overall survival. Data were presented for the first time today at the 35th Annual Meeting of the European Society for Medical Oncology (ESMO).
Millions of lives are threatened by the dual epidemics of diabetes and obesity that are bound to explode in this century, international diabetes and obesity organizations said today in the run up to World Diabetes Day.
Compliance with proposed emergency department length of stay measures for admitted, discharged, transferred, and observed patients does not differ significantly between safety-net hospitals (which serve higher proportion of patients with poorer health care status) and non-safety-net hospitals, addressing the issue of whether safety-net hospitals may not be able to meet certain performance measures and could be at risk of reduced funding, according to a study in the February 1 issue of JAMA.
Researchers in the UK have warned that a widespread mutation that has arisen in the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) appears to escape recognition by CD8 T-cell responses in both convalescent patients and recipients of the current coronavirus disease 2019 (COVID-19) vaccines.
› Verified 8 days ago
| Entity Name | Kaiser Foundation Health Plan Of The Mid-atlantic States,inc |
|---|---|
| Entity Type | Part B Supplier - Ambulatory Surgical Center |
| Entity Identifiers | NPI Number: 1366781700 PECOS PAC ID: 3779495858 Enrollment ID: O20130507000207 |
News Archive
Neuralstem, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to initiate a Phase Ia safety trial to test NSI-189, its first small molecule compound, in major depression. NSI-189 is a proprietary new chemical entity discovered by Neuralstem that stimulates new neuron growth in the hippocampus, an area of the brain that is believed to be involved in depression and other diseases, such as Alzheimer's disease.
Eli Lilly and Company announced today that its global Phase III trial evaluating ALIMTA (pemetrexed for injection) in combination with cisplatin in patients with recurrent or metastatic squamous cell cancer of the head and neck (SCCHN) did not meet its primary endpoint for overall survival. Data were presented for the first time today at the 35th Annual Meeting of the European Society for Medical Oncology (ESMO).
Millions of lives are threatened by the dual epidemics of diabetes and obesity that are bound to explode in this century, international diabetes and obesity organizations said today in the run up to World Diabetes Day.
Compliance with proposed emergency department length of stay measures for admitted, discharged, transferred, and observed patients does not differ significantly between safety-net hospitals (which serve higher proportion of patients with poorer health care status) and non-safety-net hospitals, addressing the issue of whether safety-net hospitals may not be able to meet certain performance measures and could be at risk of reduced funding, according to a study in the February 1 issue of JAMA.
Researchers in the UK have warned that a widespread mutation that has arisen in the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) appears to escape recognition by CD8 T-cell responses in both convalescent patients and recipients of the current coronavirus disease 2019 (COVID-19) vaccines.
› Verified 8 days ago
| Entity Name | Kaiser Foundation Health Plan Of The Mid-atlantic States,inc |
|---|---|
| Entity Type | Part B Supplier - Ambulatory Surgical Center |
| Entity Identifiers | NPI Number: 1497023188 PECOS PAC ID: 3779495858 Enrollment ID: O20131029000108 |
News Archive
Neuralstem, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to initiate a Phase Ia safety trial to test NSI-189, its first small molecule compound, in major depression. NSI-189 is a proprietary new chemical entity discovered by Neuralstem that stimulates new neuron growth in the hippocampus, an area of the brain that is believed to be involved in depression and other diseases, such as Alzheimer's disease.
Eli Lilly and Company announced today that its global Phase III trial evaluating ALIMTA (pemetrexed for injection) in combination with cisplatin in patients with recurrent or metastatic squamous cell cancer of the head and neck (SCCHN) did not meet its primary endpoint for overall survival. Data were presented for the first time today at the 35th Annual Meeting of the European Society for Medical Oncology (ESMO).
Millions of lives are threatened by the dual epidemics of diabetes and obesity that are bound to explode in this century, international diabetes and obesity organizations said today in the run up to World Diabetes Day.
Compliance with proposed emergency department length of stay measures for admitted, discharged, transferred, and observed patients does not differ significantly between safety-net hospitals (which serve higher proportion of patients with poorer health care status) and non-safety-net hospitals, addressing the issue of whether safety-net hospitals may not be able to meet certain performance measures and could be at risk of reduced funding, according to a study in the February 1 issue of JAMA.
Researchers in the UK have warned that a widespread mutation that has arisen in the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) appears to escape recognition by CD8 T-cell responses in both convalescent patients and recipients of the current coronavirus disease 2019 (COVID-19) vaccines.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Min-shue Alvin Chen, MD 1221 Mercantile Ln, Upper Marlboro, MD 20774-5374 Ph: () - | Dr Min-shue Alvin Chen, MD 1221 Mercantile Ln, Upper Marlboro, MD 20774-5374 Ph: (301) 386-6718 |
News Archive
Neuralstem, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to initiate a Phase Ia safety trial to test NSI-189, its first small molecule compound, in major depression. NSI-189 is a proprietary new chemical entity discovered by Neuralstem that stimulates new neuron growth in the hippocampus, an area of the brain that is believed to be involved in depression and other diseases, such as Alzheimer's disease.
Eli Lilly and Company announced today that its global Phase III trial evaluating ALIMTA (pemetrexed for injection) in combination with cisplatin in patients with recurrent or metastatic squamous cell cancer of the head and neck (SCCHN) did not meet its primary endpoint for overall survival. Data were presented for the first time today at the 35th Annual Meeting of the European Society for Medical Oncology (ESMO).
Millions of lives are threatened by the dual epidemics of diabetes and obesity that are bound to explode in this century, international diabetes and obesity organizations said today in the run up to World Diabetes Day.
Compliance with proposed emergency department length of stay measures for admitted, discharged, transferred, and observed patients does not differ significantly between safety-net hospitals (which serve higher proportion of patients with poorer health care status) and non-safety-net hospitals, addressing the issue of whether safety-net hospitals may not be able to meet certain performance measures and could be at risk of reduced funding, according to a study in the February 1 issue of JAMA.
Researchers in the UK have warned that a widespread mutation that has arisen in the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) appears to escape recognition by CD8 T-cell responses in both convalescent patients and recipients of the current coronavirus disease 2019 (COVID-19) vaccines.
› Verified 8 days ago
Dr. Enyinnaya Rose Nwaneri, M.D.,M.P.H. Anesthesiology Medicare: Medicare Enrolled Practice Location: 1221 Mercantile Ln, Upper Marlboro, MD 20774 Phone: 301-395-2074 | |
Sasha Rochelle Jarrett, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 1221 Mercantile Ln, Upper Marlboro, MD 20774 Phone: 301-456-4368 | |
Weijia Xia Yan, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 1221 Mercantile Ln, Upper Marlboro, MD 20774 Phone: 361-855-0001 | |
Dr. Megan Campion, M.D. Anesthesiology Medicare: Medicare Enrolled Practice Location: Largo Medical Center, 1221 Mercantile Ln, Upper Marlboro, MD 20774 Phone: 301-618-5500 | |
Harold T. Rowson, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 5714 Kenfield Ln, Upper Marlboro, MD 20772 Phone: 301-325-3558 | |
Dr. Jonathan Tze-wei Ho, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1221 Mercantile Ln, Upper Marlboro, MD 20774 Phone: 202-306-5341 |